Metastatic Gallbladder Cancer: What to Ask

Gallbladder cancer is called metastatic when it has spread beyond the gallbladder and the nearby lymph nodes to another organ. The liver and the lining of the abdomen are the usual places. NCI groups three situations together for treatment purposes: unresectable, metastatic, and recurrent disease.

NCI states the outlook for that group directly. These cancers are not curable. It also states two things that get lost when people read only the first sentence. Symptoms can be improved a great deal by relieving a blocked bile duct. And a few people have very slow-growing tumors and live several years.

Gallbladder cancer is uncommon. For 2026 the American Cancer Society estimates about 12,640 new cancers of the gallbladder and nearby large bile ducts in the United States, along with roughly 4,590 deaths; only about 4 in 10 of those new cases are gallbladder cancer itself. NCI's PDQ summary opens with the same pair of measures but is still printing the 2025 edition, credited to the Society as its reference 1. That rarity shapes almost everything below, including which trials your cancer was studied in.

The most common symptoms of gallbladder cancer are jaundice, pain and fever. Jaundice means bile is backing up because the duct is blocked. That single problem can stop chemotherapy before it starts, because the drugs are cleared by the liver.

NCI's preferred approaches for relieving a blockage are percutaneous transhepatic drainage, which is a drain placed through the skin into the liver, or a stent placed by endoscopy. Surgical bypass is used when neither of those is possible. Relief is warranted when itching and liver dysfunction are outweighing the cancer's other symptoms.

Questions worth asking at this stage:

• Is my bilirubin high enough to delay chemotherapy, and what number does it need to reach before treatment can start?
• Would a stent placed by endoscopy work for me, or does the blockage need a drain through the skin?
• Who do I call if the drain stops working or I develop a fever?

For decades the base regimen has been gemcitabine plus cisplatin. It comes from a phase III trial of 410 people with unresectable, metastatic or recurrent biliary tract cancer, randomly assigned to gemcitabine with or without cisplatin for up to 6 months. Median overall survival was 11.7 months with the pair versus 8.1 months with gemcitabine alone. The hazard ratio was 0.64. The benefit held across subgroups, including the 149 people in the trial who had gallbladder cancer specifically.

The trade-off was measurable too. The combination caused more blood count toxicity. Gemcitabine alone caused more liver toxicity.

Two large phase III trials then tested adding a checkpoint inhibitor to that backbone.

TOPAZ-1 (NCT03875235) enrolled 685 people with untreated advanced biliary tract cancer. They received durvalumab or placebo along with cisplatin and gemcitabine for up to eight cycles, then durvalumab or placebo alone until the cancer progressed. Median overall survival was 12.9 months with durvalumab and 11.3 months with placebo, with a hazard ratio of 0.76.

The survival curve matters more than the median here. At 18 months, 35.1 percent of the durvalumab group were alive, versus 25.5 percent on placebo. At 24 months it was 24.9 percent versus 10.4 percent. There was no significant difference in serious treatment-related side effects between the groups.

KEYNOTE-966 (NCT04003636) enrolled 1,069 people and tested pembrolizumab the same way, for up to 35 cycles. Median overall survival was 12.7 months versus 10.9 months, hazard ratio 0.83. Treatment-related deaths occurred in 8 patients (2 percent) on pembrolizumab and 3 (1 percent) on placebo.

There is also a trial run specifically in unresectable gallbladder cancer, which is rare enough to be worth knowing about. It compared best supportive care, weekly fluorouracil with folinic acid, and modified gemcitabine plus oxaliplatin. Median survival was 4.5 months, 4.6 months and 9.5 months respectively.

NCI is specific about one test. Everyone with unresectable, metastatic or recurrent disease who has not already had a checkpoint inhibitor should have molecular testing for deficient mismatch repair (dMMR) or high microsatellite instability (MSI-H). These describe a tumor whose DNA proofreading is broken. If either is found, pembrolizumab can be considered, based on results from the I-PREDICT and KEYNOTE-158 studies.

NCI adds that testing for IDH1 variants, FGFR2 gene fusions and HER2 expression may point to targets available in clinical trials. It also notes that targeted drugs FDA-approved as second-line treatment for cholangiocarcinoma, the bile duct cancer next door, could likely be used in appropriate gallbladder cancer patients. Our page on biomarker testing explains how these tests are ordered and what a report looks like.

One more genetic test is about safety rather than targets. The DPYD gene controls how the body breaks down capecitabine and fluorouracil. An estimated 1 to 2 percent of people carry a harmful DPYD variant. People with the DPYD*2A variant who receive these drugs can have severe, sometimes fatal toxicity. Depending on the result, the drug may be avoided or the dose cut by 50 percent. NCI notes DPYD testing costs under $200, that insurance coverage varies, and that waiting for it can delay treatment by about two weeks.

• What exactly is the goal of the treatment you are proposing: shrinking the cancer, holding it steady, or easing symptoms?
• Has my tumor been tested for dMMR or MSI-H, and if there is not enough tissue, can a blood test be used?
• Would you add durvalumab or pembrolizumab to gemcitabine and cisplatin for me, and what would change if I said no?
• Should I have DPYD testing before any capecitabine or fluorouracil?
• How many biliary tract cancers does this team treat a year, and will my case go to a tumor board?
• Which trials are open here or within driving distance, and does eligibility depend on starting them before other treatment?

Most trials in this field enroll all biliary tract cancers together rather than gallbladder cancer alone. NCI warns that results must be applied to gallbladder cancer with caution for exactly that reason. It is fair to ask how many people with gallbladder cancer were in the trial behind your plan.

Biliary obstruction and infection can come back quickly, and both are treatable when caught early.

• Call 911 or go to an emergency department if fever or shaking chills come with confusion, feeling faint, or a racing heart. An infected bile duct can move into the bloodstream fast. Go too if you vomit blood or pass black tarry stools, or if belly pain is sudden, severe and your abdomen feels hard. Once gemcitabine and cisplatin have started, any fever of 100.4°F (38°C) or higher belongs here too, with or without those other signs. That combination lowers blood counts, and CDC calls a fever on chemotherapy a medical emergency, so head in rather than phoning and waiting.
• Call your care team the same day if a fever of 100.4°F (38°C) or higher or shaking chills appear before chemotherapy has begun, above all if you have a biliary stent or drain, because fever here often means the bile duct has become blocked or infected again. Call the same day for returning or deepening yellowing of the eyes or skin, for dark urine with pale stools, for new confusion, and for a drain that stops draining, leaks around the site, or has red sore skin around it.
• Call your care team within a day or two if itching is getting worse, if upper right belly discomfort keeps building, or if nausea and vomiting are stopping you eating. On cisplatin, do the same for new ringing in your ears, a change in hearing, or numbness and tingling in your hands or feet.

Ask for these thresholds in writing, with a daytime number and a night number, and keep them where a family member can find them.

Two pages give useful background. Metastatic cancer explains what spread means across cancer types and why the original organ still names the disease. Palliative care covers symptom-focused care, which for this cancer often runs alongside chemotherapy from the beginning rather than at the end. For the disease itself, start with gallbladder cancer.

• NCI PDQ: gallbladder cancer treatment, health professional version
• NCI PDQ: gallbladder cancer treatment, patient version
• American Cancer Society: Cancer Facts & Figures
• American Cancer Society: key statistics for gallbladder cancer
• ClinicalTrials.gov: TOPAZ-1, NCT03875235
• ClinicalTrials.gov: KEYNOTE-966, NCT04003636
• MedlinePlus: cholangitis
• NCI: infection and neutropenia during cancer treatment
• CDC: watch out for fever (preventing infections in cancer patients)